Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Change in Receivables (2020 - 2025)

Insight Molecular Diagnostics' Change in Receivables history spans 6 years, with the latest figure at -$254000.0 for Q3 2025.

  • For Q3 2025, Change in Receivables fell 304.84% year-over-year to -$254000.0; the TTM value through Sep 2025 reached $49000.0, up 119.29%, while the annual FY2024 figure was $1.1 million, 1135.78% up from the prior year.
  • Change in Receivables for Q3 2025 was -$254000.0 at Insight Molecular Diagnostics, up from -$3.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.9 million in Q1 2025 and bottomed at -$3.0 million in Q2 2025.
  • The 5-year median for Change in Receivables is $22000.0 (2022), against an average of $77315.8.
  • The largest annual shift saw Change in Receivables skyrocketed 6585.71% in 2024 before it plummeted 3884.21% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $405000.0 in 2021, then crashed by 94.57% to $22000.0 in 2022, then dropped by 4.55% to $21000.0 in 2023, then surged by 6585.71% to $1.4 million in 2024, then tumbled by 118.09% to -$254000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Change in Receivables are -$254000.0 (Q3 2025), -$3.0 million (Q2 2025), and $1.9 million (Q1 2025).